A Clinical Study to Evaluate the Breast Milk, Plasma and Whole Blood Pharmacokinetics of MK-8527 in Healthy Lactating Female Participants
Latest Information Update: 20 Dec 2024
Price :
$35 *
At a glance
- Drugs MK-8527 (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 17 Dec 2024 Planned End Date changed from 2 Jan 2026 to 19 Dec 2025.
- 17 Dec 2024 Planned initiation date changed from 18 Dec 2024 to 22 Jan 2025.
- 20 Nov 2024 Planned End Date changed from 19 Dec 2025 to 2 Jan 2026.